Narrow band ultraviolet B therapy deactivates Th1/Th17 pathway and activates Th2 cytokines secretion in Egyptian psoriatic arthritis patients

Farid, Alyaa; Tawfik, Ali; Elsioufy, Basil; Safwat, Gehan

doi:10.1080/16878507.2020.1742443

Cited by 13 publications

(7 citation statements)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Experimentally, administration of IL-10 resulted in shift-type 1 cytokines to type 2 cytokines. In addition, the treatment effect of ultraviolet light on the modulation of inflammation by up-regulation of the IL-10 in keratinocytes has been previously shown [30]. On the other hand, decreasing the level of IL-10 has been demonstrated to consider a critical way to induce disease flare-ups in the psoriatic skin [31].…”

Section: Discussionmentioning

confidence: 98%

The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

Akbarzadeh

Alirezaei

Doosti-Irani

et al. 2022

Dermatology Research and Practice

View full text Add to dashboard Cite

Background. Attention to the administration of probiotics for the treatment of psoriasis has recently increased. Aim. In the present study, improvements in dermatology life quality index (DLQI), psoriasis area severity index (PASI), and visual analogue scale (VAS) scores in the psoriasis patients receiving Lactocare® probiotic were compared to psoriasis patients receiving placebo. Methods. A total of 52 psoriasis patients were included in this study and randomly divided into treatment and placebo (control) groups. The control group received topical hydrocortisone associated with placebo; in the treatment group, Lactocare® was administrated orally associated with hydrocortisone. The mean of VAS, DLQI, and PSAI scores was recorded and evaluated pretreatment and post-treatment in both groups for 3 months. The mean of the scores in the control groups was compared to the treatment group. Intragroup analysis was preformed with a comparison of the mean of these scores at baseline 4-, 8-, and 12-weeks post-treatment. Results. In the treatment group, a significant decrease was seen in PASI, VAS, and DLQI scores compared to the control group on week 12 post-treatment. Conclusion. Oral administration of Lactocare® probiotic (two times daily) associated with administration of topical hydrocortisone resulted in the improvement of PASI, DLQI, and VAS scores in the patients with psoriasis after 12 weeks of treatment. PASI reduction occurred in all patients who received probiotics.

show abstract

Section: Discussionmentioning

confidence: 98%

The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

Akbarzadeh

Alirezaei

Doosti-Irani

et al. 2022

Dermatology Research and Practice

View full text Add to dashboard Cite

show abstract

“…NB-UVB suppresses type I and type II interferons (IFNs), and T helper (Th) 17 signaling pathways 13 . NB-UVB treatment suppresses serum levels of psoriasis-driving cytokines, such as tumor necrosis factor (TNF)-α, IL-8, IL-12, IL-17, IL-22, IL-23, and IL-34 and elevates the levels of IL-10, an anti-inflammatory cytokine, in patients with psoriasis 14,15 . Moreover, NB-UVB treatment significantly suppresses the mRNA levels of nuclear factor-kappa-B inhibitor zeta, serpin family B member 4 (SERPINB4), autophagy related 13, and cathepsin S in the edges of psoriatic plaques 16 and may attenuate TLR-3/4/9 activity in psoriatic plaques 17 .…”

mentioning

confidence: 99%

Elucidating the NB-UVB mechanism by comparing transcriptome alteration on the edge and center of psoriatic plaques

Boonpethkaew

Meephansan

Charoensuksira

et al. 2023

Sci Rep

View full text Add to dashboard Cite

Narrow band-ultraviolet B (NB-UVB) is an effective treatment for psoriasis. We aim to generate a potential mechanism of NB-UVB through comparing the transcriptomic profile before and after NB-UVB treatment between the peripheral edge of lesional skin (PE skin) and the center of lesional skin (CE skin) on the basis of molecular mechanisms of these two areas display different downstream functions. More than one-fourth of the NB-UVB-altered genes were found to be plaque-specific. Some of them were psoriasis signature genes that were downregulated by NB-UVB in, both, PE and CE skin (core alteration), such as IL36G, DEFB4A/B, S100A15, KRT16, and KRT6A. After NB-UVB treatment, the activity score of upstream cytokines, such as interferons, interleukin (IL)-6, IL-17, and IL-22 in pathogenesis decreased. In addition, NB-UVB could restore normal keratinization by upregulating LORICRIN and KRT2, particularly in the CE skin. Finally, we illustrated that NB-UVB is capable of suppressing molecules from the initiation to maintenance phase of plaque formation, thereby normalizing psoriatic plaques. This finding supports the usefulness of NB-UVB treatment in clinical practice and may help in the development of new treatment approaches in which NB-UVB treatment is included for patients with psoriasis or other inflammatory skin diseases.

show abstract

“…In a study involving 80 patients diagnosed with psoriasis, NB-UVB was shown to significantly reduce serum interleukin (IL)-12, IL-17, and IL-23 levels, thus deactivating the T-helper-1 and T-helper-17 pathways. 18 In another study, NB-UVB-treated psoriasis patients had decreased levels of IL-1b, IL-2, IL-5, and IL-6, along with elevated levels of the anti-inflammatory cytokine IL-10. 19 Ultraviolet B causes Langerhans cells to migrate from the epidermis, thereby reducing their numbers and functions in the epidermis, but NB-UVB is less potent in inducing this effect compared to broadband ultraviolet B.…”

Section: Discussionmentioning

confidence: 96%

The effect of phototherapy on Demodex density: a case–control study

Aksoy,

Aslan Kayıran,

Dede

et al. 2024

Int J Dermatology

View full text Add to dashboard Cite

BackgroundHuman Demodex mites, Demodex folliculorum and Demodex brevis, are microorganisms that reside in the pilosebaceous units, usually without causing symptoms. Phototherapy has been linked to demodicosis in previous studies. We aimed to determine whether there was an increase in the frequency of demodicosis and Demodex density after 20 phototherapy sessions.MethodsA case–control study was conducted with 32 participants who received narrowband ultraviolet B or ultraviolet A‐1 therapy for various dermatological indications. Standardized skin surface biopsies were performed before and after phototherapy to assess Demodex density. The presence of Demodex‐related skin conditions was assessed before phototherapy. A statistical analysis was performed to compare the Demodex densities and prevalence of demodicosis between the baseline and 20th session of phototherapy.ResultsNo significant change was observed in Demodex density after 20 sessions of phototherapy. The average Demodex density before treatment was 2.75 ± 4.48 (/cm2), and after treatment, it was 2.85 ± 4.81 (/cm2), indicating no significant difference (P = 0.879). The percentage of patients with demodicosis in at least one region of the face was 28.1% (9/32) before treatment, and after treatment, it was 31.3% (10/32), with no significant difference (P = 1.00).ConclusionsOur findings contradict previous studies that suggested an increased Demodex density and demodicosis prevalence after phototherapy. The data from previous studies are open to debate due to their selected samples, designs, and interpretations regarding the phototherapy–immunosuppression–Demodex relationship. Larger‐scale longitudinal studies conducted on a homogeneous sample are warranted to better understand the relationship between phototherapy and demodicosis.

show abstract

Narrow band ultraviolet B therapy deactivates Th1/Th17 pathway and activates Th2 cytokines secretion in Egyptian psoriatic arthritis patients

Abstract: Narrow band ultraviolet B therapy deactivates Th1/Th17 pathway and activates Th2 cytokines secretion in Egyptian psoriatic arthritis patients,

Cited by 13 publications

References 53 publications

The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

The Efficacy of Lactocare® Synbiotic on the Clinical Symptoms in Patients with Psoriasis: A Randomized, Double‐Blind, Placebo‐Controlled Clinical Trial

Elucidating the NB-UVB mechanism by comparing transcriptome alteration on the edge and center of psoriatic plaques

The effect of phototherapy on Demodex density: a case–control study

Contact Info

Product

Resources

About